ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2571

Pigment Epithelium Derived Factor Secreted By Activated Fibroblasts Can Contribute To Impaired Angio and Vasculogenesis In Scleroderma

Vasiliki Liakouli1,2, Georgia Mavria3, Justin Gillespie4, Margherita Scarcia3, Paola Cipriani2, Roberto Giacomelli2, Paul Emery5 and Francesco Del Galdo5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Leeds, United Kingdom, 2Rheumatology Unit, University of Aquila, L'Aquila, IT, L'Aquila, Italy, 3Signal Transduction and Angiogenesis group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, fibroblasts and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disorder characterized by tissue fibrosis and vasculopathy. This latter comprises both neointima proliferation and defective angio and vasculogenesis. Although some of the clinical manifestations of the vasculopathy often precede the onset of fibrosis, there is scanty of data investigating the molecular mechanisms eventually linking the profibrotic activation of fibroblasts (FBs) and the poor angio/vasculogenesis in Scleroderma. Recently, a proteomic analysis of the secretome of SSc dermal FBs (SSc FBs), identified among other proteins a consistent increased secretion of Pigment Epithelium Derived Factor (PEDF) associated with the profibrotic phenotype (AJP, 2010). PEDF has been described as produced by retinal-pigmented epithelium and melanocytes, and is a major endogenous inhibitor of intraocular angiogenesis. Here we aimed to validate the increased expression of PEDF in SSc and test the hypothesis that PEDF might play an important role in establishing or perpetuating SSc vasculopathy.

Methods: PEDF expression was investigated in the involved skin and FBs of 4 SSc patients in the early phase of the diffuse form of the disease and 4 healthy controls (HC) by immunohistochemistry (IHC) and real time-PCR analysis. Functional effects of PEDF on angio/vasculogenesis were examined by Matrigel assays. Organotypic co-culture assays were performed seeding HUVECs or microvascular endothelial cells (MVECs), on monolayers of either primary healthy FBs (HC FBs) or SSc FBs or HC FBS silenced for Caveolin-1 (Cav-1). Endothelial cells were evidenced by IHC staining for CD31 in organotypic co-culture assays. Vascular tubule number, length and junctions were identified and analyzed by Angiosys software (TCS CellWorks).

Results: Both Healthy and Scleroderma skin biopsies showed high PEDF protein expression on melanocytes, as expected. Nevertheless, in SSc skin 52% (+/-5.9) of the FBs showed a strong expression of PEDF whereas only 13% (+/-0.68) of the FBs in HC skin were positive (p<0.0006). Double IHC studies indicated that FBs positive for PEDF showed a decreased expression of Cav-1 in both HC and SSc skin. In vitro studies confirmed that SSc FBs showed on average a 5-fold increased in PEDF expression compared to HC FBs (p<0.05). Functional studies confirmed that recombinant PEDF protein had a direct inhibitory effect on vasculogenesis, suppressing both tubule length and number. Consistently, organotypic co-culture assays indicated that SSc FBs or HC FBs silenced for Cav-1 inhibited tubulogenesis both on MVECs or HUVECs, respectively.

Conclusion: PEDF expression is increased in SSc biopsies and SSc FBs. PEDF expression is associated with decreased Cav-1 expression in vivo and it is induced by silencing Cav-1 in vitro. Functionally, PEDF can suppress vasculogenesis both in Matrigel and co-culture assays. This suggests that the decreased expression of Cav-1 observed in SSc FBs may contribute to the vasculopathy of Scleroderma. Further studies unraveling the mechanisms of the antiangiogenic effect of PEDF may shed light in understanding the molecular events linking the profibrotic phenotype and SSc vasculopathy.


Disclosure:

V. Liakouli,
None;

G. Mavria,
None;

J. Gillespie,
None;

M. Scarcia,
None;

P. Cipriani,
None;

R. Giacomelli,
None;

P. Emery,
None;

F. Del Galdo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pigment-epithelium-derived-factor-secreted-by-activated-fibroblasts-can-contribute-to-impaired-angio-and-vasculogenesis-in-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology